Clinical trial · Observational
Biomarkers in Samples From Patients With Endometrial Cancer
Specialized Program of Research Excellence (SPORE) in Endometrial Cancer
NCT01199250CI-TRIAL-00079807withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Not a treatment/applicable clinical trial
Summary
Brief summary (as posted)
This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lynch Syndrome | — | UNRESOLVED | — |
| Recurrent Uterine Corpus Carcinoma | — | UNRESOLVED | — |
| Stage III Uterine Corpus Cancer | Malignant Uterine Corpus Neoplasm | CURATED_BROADER | 0.78 |
| Stage II Uterine Corpus Cancer | Malignant Uterine Corpus Neoplasm | CURATED_BROADER | 0.78 |
| Stage I Uterine Corpus Cancer | Malignant Uterine Corpus Neoplasm | CURATED_BROADER | 0.78 |
| Stage IV Uterine Corpus Cancer | Malignant Uterine Corpus Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Basic science (biomarker analysis)
- description
- Previously collected samples are analyzed for biomarker and other laboratory analyses.
- interventionNames
- Other: Laboratory Biomarker Analysis
Primary outcomes (12)
- measure
- Clinical sensitivity and specificity of epigenetic biomarkers in a cohort of blind samples (Project 2)
- timeFrame
- 1 month
- description
- ROC curves used to describe the discriminatory characteristics of candidate biomarkers. From the competing risk model, the coefficients of the clinicopathological covariates and the hypermethylation levels of each biomarker will indicate the association of these factors with each of the four types of survivals. The significance of association will be indicated by P-values, and hazard rates will also be provided.
- measure
- Confirmation of CpG island loci frequently hypermethylated in EECs exhibiting recurrence (Project 2)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Samples available from one of the following: * GOG-0210 * Washington University School of Medicine Siteman Cancer Center
References
Publications (0)
Data not yet available
No reference posted for this study.